Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study
After optimally balancing prognostic factors, regular mRNA vaccine boosters at the onset of ICIs did not impact the safety and survival of patients with advanced NSCLC. The improved outcome observed in patients with high PD-L1 expression levels aligns with previous findings and warrants further investigation.
Authors
- Fabrizio Nelli (ORCID: https://orcid.org/0000-0001-8374-1362)
- Agnese Fabbri (ORCID: https://orcid.org/0000-0002-3357-6343)
- Alessandro Raso (ORCID: https://orcid.org/0000-0003-1273-9905)
- Enzo Maria Ruggeri (ORCID: https://orcid.org/0000-0001-7790-0056)
- Carlo Signorelli (ORCID: https://orcid.org/0000-0001-9710-4962)
- Daniele Remotti (ORCID: https://orcid.org/0009-0009-9428-9207)
- Diana Giannarelli (ORCID: https://orcid.org/0000-0002-6085-1195)
- Antonella Virtuoso (ORCID: https://orcid.org/0000-0001-8888-9657)
- Fabrizio Chegai (ORCID: https://orcid.org/0000-0001-8736-6475)
Institutions
- Ospedale di Belcolle (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-06-11
- DOI
- https://doi.org/10.3390/cancers17121948
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14